Reissue Cannot Correct Judgment Errors
Client Alert | 2 min read | 03.13.07
The Federal Circuit, in In re Arnold B. Serenkin (No. 06-1242; March 6, 2007), affirms a final decision of the United States Patent and Trademark Office Board of Patent Appeals and Interferences (“Board”), maintaining the Examiner’s rejection of claims 1-11 of Serenkin’s reissue application. In so doing, the Court holds that the Board correctly determined that the error upon which Serenkin bases his reissue application is not a correctable error under 35 U.S.C. § 251.
Serenkin submitted a PCT application to the United States Receiving Office (“USRO”), one day less than a year after the filing date of the provisional application to which it claimed priority. The provisional application contained eight sheets of drawings, the PCT application referenced these drawings but did not include the drawings. The USRO sent notice to Serenkin indicating that he had the choice of either submitting the drawings and receiving a new international filing date, or proceeding without the drawings and retaining the original filing date. The USRO notice specifically stated that if Serenkin chose the latter, the original priority date would be lost. Serenkin submitted the drawings and accepted a new international filing date. The US national phase of the PCT application subsequently issued as a U.S. patent. Serenkin then sought reissue of the patent, seeking to obtain the benefit of the filing date of the original provisional patent. The Examiner issued a final rejection of the reissue application concluding that “the error which is relied upon to support the reissue application is not an error upon which a reissue can be based.” In upholding this rejection, the Board noted that Serenkin failed to obtain the benefit of the earlier filing date, not because of inadvertence, accident or mistake, which are correctable by reissue under § 251, but because of a deliberate choice, which it construed as an error of judgment.
While acknowledging that § 251 is "based on fundamental principles of equity and fairness, and should be construed liberally," the Federal Circuit panel distinguishes the case at hand from those where a patent applicant inadvertently failed to perfect a priority claim. The Court notes that the present case is “about an applicant who intentionally and knowingly surrendered his right to a claim of priority, in exchange for a benefit, and now is unhappy with his choice.”
Insights
Client Alert | 2 min read | 02.03.26
CMS Doubles Down on RADV Audit Changes
On January 27, 2026, the Centers for Medicare and Medicaid Services (CMS) released a Health Plan Management System (HPMS) memo that provided a long-awaited update on how the agency plans to approach previously announced Risk Adjustment Data Validation (RADV) audits for Payment Years (PY) 2020-2024. The memo is the agency’s most comprehensive statement on the subject since September 25, 2025, when the Northern District of Texas vacated the 2023 RADV Final Rule. The memo makes clear that, while CMS has made certain operational adjustments in response to concerns expressed by Medicare Advantage Organizations (MAOs), the agency is largely pressing forward with the accelerated audit strategy announced in May 2025.
Client Alert | 7 min read | 01.30.26
CMS Proposes CY 2027 Growth Rate and Changes to Risk Adjustment for Medicare Parts C and D
Client Alert | 4 min read | 01.30.26
Optimum’s Shot Across the Bow: An Antitrust Challenge to Cooperation Agreements
Client Alert | 9 min read | 01.30.26
